DOCSLIB.ORG

Neuroprotective Effect of Citicoline on Retinal Cell Damage Induced by Kainic Acid in Rats

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuroprotective Effect of Citicoline on Retinal Cell Damage Induced by Kainic Acid in Rats Neuroprotective Effect of Citicoline on Retinal Cell Damage Induced by Kainic Acid in Rats Yong Seop Han, MD, In Young Chung, MD, Jong Moon Park, MD, PhD, Ji Myeong Yu, MD, PhD Department of Ophthalmology, College of Medicine, Gyeongsang National University, Jinju, Korea Purpose: To examine whether citicoline has a neuroprotective effect on kainic acid (KA)-induced retinal damage. Methods: KA (6 nmol) was injected into the vitreous of rat eyes. Citicoline (500mg/kg, i.p.) was administered to the rats once before and twice a day after KA-injection for 3- and 7-day intervals. The neuroprotective effects of citicoline were estimated by measuring the thickness of the various retinal layers using hematoxylin-eosin (H&E) staining. In addition, immunohistochemistry was conducted to elucidate the expression of endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS). Results: Morphometric analysis of retinal damage in KA-injected eyes showed significant cell loss in the inner nuclear layer (INL) and inner plexiform layer (IPL) of the retinas at 3 and 7 days after KA injection, but not in the outer nuclear layer (ONL). At 3 days after citicoline treatment, no significant changes were detected in the retinal thickness and immunoreactivities of eNOS and nNOS. The immunoreactivities of eNOS and nNOS increased in the retina at 7 days after the KA injection. However, prolonged treatment for 7 days significantly attenuated the immunoreactivities and the reduction of thickness. Conclusions: The results indicate that citicoline has a neuroprotective effect on KA-induced neurotoxicity in the retina. Korean Journal of Ophthalmology 19(3):219-226, 2005 Key Words: Citicoline, Kainic acid, Neuroprotective effect, NOS Retinal ischemic injuries are known to be associated with increases oxygen consumption.13-15 The generation of nitric excitotoxicity of glutamate.1,2 It is generally believed that oxide (NO) and NOS following the process described above ischemia caused by elevated intraocular pressure (IOP), triggers the fragmentation of DNA, which in turn leads to which elicits mechanical damage to the retinal cells or retinal ganglion cell death through the elevation of p53.16 impedes blood flow, plays an important role in the mecha- NO mediates several biological actions, including relax- nism of how retinal ganglion cell death occurred.3-7 In ation of blood vessels and cytotoxicity, and acts as gaseous addition to retinal ischemia, excitotoxicity of glutamate, lack neurotransmitters in the central and peripheral nervous of neurotrophin and oxidative damage are also discussed as system.17,18 Also, it plays an important role in neuronal possible causes of retinal ganglion cell death.8,9 damage in the CNS following brain ischemia, and the In a hypoxic state, there is a large release of the excitatory administration of NOS inhibitors protected the retina from neurotransmitter, glutamate, into the extracellular space10-12 degenerative changes and provided protection of retinal and resultant glutamate excitotoxicity, which is promoted by ganglion cells from ischemic damage.19-23 N methyl D aspartate (NMDA) and kainate receptors. The Citicoline (Cytidine-5-diphosphocholine, exogenous CDP- excitotoxicity induced by kainic acid (KA), a glutamate choline), first synthesized by Eugene Kennedy in 1956, has analogue, involves a process in which AMPA/KA receptors proved effective in treating a wide range of cognitive are overstimulated, which in turn leads to Na＋ influx, cell disorders caused by CNS ischemia, brain injury and depolarization and eventually excessive influx of Ca2＋ as the Parkinson's disease.24,25 Endogenous CDP-choline is a key voltage-dependent Ca2＋ channel become permeable to Ca2＋. intermediary in the biosynthesis of phosphatidylcholine Excessive accumulation of Ca2＋ by neural cells activates (PtdCho). Increased biosynthesis of PtdCho prevents neuronal cellular proteases and nitric oxide synthase (NOS) and apoptosis and promotes neuroprotection. Citicoline is also known to preserve cardiolipin and sphingomyelin, stimulate glutathione biosynthesis, increase the activity of glutathione Received: May 12, 2005 Accepted: August 25, 2005 24,25 reductase and reduce lipid peroxidation. Reprint requests to Jong Moon Park, MD. Department of Ophthal- mology, College of Medicine, Gyeongsang National University, #92 This study aimed to evaluate the neuroprotective effects of Chillam-dong, Jinju, Gyeong-nam 660-280, Korea. Tel: 82-55-750- citicoline by analyzing the morphometric features of cells and 8170, Fax: 82-55-758-4158, E-mail: [email protected] the expression of NOS in the adult rat retina after KA- 219 Kor J Ophthalmol Vol.19, No.3, 2005 induced injuries. nitrogen and then stored at -70℃ until sectioning. The tissues were kept at -20℃ for an hour for sectioning Materials and Methods into 12 µm-thick continuous frozen sections with a cryostat (Leica, Meyer Instruments, Inc. Houston, TX). The sections 1. Sample animals preparation were mounted on gelatin-coated slides, dried for 30 minutes at 42℃ and stored at -70℃ until use. Sprague-Dawley (SD) white male rats (Samtaco, Osan, Korea) weighing 200-250 g were maintained in cages under 5. Morphometric features a 12-hour light and 12-hour dark cycle for a week. A total of 60 rats were divided into three groups of 20 rats each: The prepared frozen sections were kept at room rats treated with KA only, rats treated with citicoline one temperature for about an hour, dehydrated to increase the hour prior to and twice a day after the administration of KA, stickiness between the section and the slide, washed in two and normal rats (the control group). Each group were changes of distilled water for 5 minutes each and dehydrated subdivided into 3- and 7-day subgroups according to time again by water deprivation. After dehydrating, the sections duration after injection. were stained in 0.5% hematoxylin for 5 minutes, washed in two to three changes of distilled water, soaked in hydro- 2. A rat model for the study of Kainic acid-induced chloric acid for a second time and then washed in several retinal damage changes of distilled water to enhance the color after hematoxylin staining. The hematoxylin-stained sections were Each rat was intraabdominally anesthetized with a double-stained with 0.6% eosin for 2 minutes, dehydrated combination of a 30 mg/kg dose of ketamine (Yohan Keta- through a graded alcohol series (1 minute each in 70%, 80%, mine, Yohan Corporation) and a 2.5 mg/kg dose of xylazine 90%, 95%, and 100%), cleared in xylene series and mounted (Yuhan Rompun, Yuhan Corporation). The anesthetized rat permanently. Stained tissue slides were examined using a was immobilized in a stereotaxic frame and a drop of microscope and pictures were taken. To examine the morpho- ofloxacin was administered into the eye to avoid infection. metric changes of the retina after administrating KA and KA (Sigma, USA) was dissolved in 2 mM, 3 ul (6 nM) citicoline, the layer-structure of the retina thickness and of which was injected into the vitreous of the rat eyes using retinal cells in treated and control rats were assessed and 26 a 30 gauge microsyringe. An ophthalmoscopic examination compared at the location of 800-1,000 µm from the optic was performed to ensure that KA was accurately injected into nerve in five slides per rat. the vitreous of the rat eyes, after which ofloxacin was once again applied. 6. NOS immunohistochemistry 3. Citicoline administration The prepared frozen sections were kept at room temperature for about an hour and dehydrated by water After KA injection, rats were housed in separate cages deprivation. After dehydrating, the sections were washed in according to the subclassification of the 3- and 7-day groups. 0.02M phosphate buffer saline (PBS), 0.5% Triton Citicoline-treated rats received 500 mg/kg citicoline intra- X-100/0.02 M PBS and 0.02 M PBS for 15 minutes each, abdominally an hour prior to and twice a day at 12-hour treated in 0.3% H2O2 for 30 minutes to inactivate endogenous intervals after KA injection. This procedure was routinely peroxidase, and washed again in the same way as described performed without anesthesia. above. After washing, normal serum was applied to the slides, which were then incubated for 30 minutes. After 4. Tissue isolation normal serum was cleaned up, each primary antibody was applied to the slides, which were then incubated for 16 to On days 3 and 7 after KA injection, 10 rats in each sub- 18 hours at 4℃. For the primary antibodies against neuronal group were sacrificed and the eyes were rapidly enucleated. NOS (nNOS) and endothelial NOS (eNOS), mouse anti- The cornea was removed promptly from the enucleated nNOS monoclonal and mouse anti-eNOS polyclonal anti- eyeballs and then placed into 4% neutralized phosphate bodies were used. Anti-nNOS and anti-eNOS primary anti- buffered paraformaldehyde (NBP). After an hour, the lens bodies were applied at a dilution of 1:100. Unbound primary was removed and the eyeballs were fixed in the same NBP antibody was washed off with 0.02 M PBS, 0.5％ Triton for 5 hours, after which the eyeballs were washed in 0.1 M X-100/0.02 M PBS and 0.02 M PBS, for 15 minutes each. PB (phosphate buffer), and soaked for 24 hours in 30% PB The sections were subsequently reacted with secondary sucrose to prevent irreversible damage to the tissues. After antibody (biotinylated anti-mouse IgG) for 90 minutes at soaking, sucrose solution was carefully washed off the tissue room temperature. After unbound secondary antibody was surface, and the tissues were embedded in OCT compound washed off in the same way as described above, the slides (Tissue-TekⓇ), frozen in isopentane cooled with liquid were reacted for 90 minutes at room temperature using an 220 YS Han, et al. NEUROPROTECTIVE EFFECT OF CITICOLINE Avidin Biotin Complex kit (Vectastain, Vector Labs.
Load more

Recommended publications
  • Role of Citicoline in the Management of Traumatic Brain Injury
    pharmaceuticals Review Role of Citicoline in the Management of Traumatic Brain Injury Julio J. Secades Medical Department, Ferrer, 08029 Barcelona, Spain; [email protected] Abstract: Head injury is among the most devastating types of injury, specifically called Traumatic Brain Injury (TBI). There is a need to diminish the morbidity related with TBI and to improve the outcome of patients suffering TBI. Among the improvements in the treatment of TBI, neuroprotection is one of the upcoming improvements. Citicoline has been used in the management of brain ischemia related disorders, such as TBI. Citicoline has biochemical, pharmacological, and pharmacokinetic characteristics that make it a potentially useful neuroprotective drug for the management of TBI. A short review of these characteristics is included in this paper. Moreover, a narrative review of almost all the published or communicated studies performed with this drug in the management of patients with head injury is included. Based on the results obtained in these clinical studies, it is possible to conclude that citicoline is able to accelerate the recovery of consciousness and to improve the outcome of this kind of patient, with an excellent safety profile. Thus, citicoline could have a potential role in the management of TBI. Keywords: CDP-choline; citicoline; pharmacological neuroprotection; brain ischemia; traumatic brain injury; head injury Citation: Secades, J.J. Role of 1. Introduction Citicoline in the Management of Traumatic brain injury (TBI) is among the most devastating types of injury and can Traumatic Brain Injury. result in a different profile of neurological and cognitive deficits, and even death in the most Pharmaceuticals 2021, 14, 410.
    [Show full text]
  • Eletriptan Smpc
    For the use only of a neurologist/ specialist or a Hospital or a Laboratory Generic Name Citicoline Trade Name Ceham 1. NAME OF THE MEDICINAL PRODUCT: Citicoline 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each film coated tablet contains: Citicoline sodium equivalent to Citicoline……………………………500mg 3. PHARMACEUTICAL FORM: Film coated tablet 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications: For the treatment of disturbance of consciousness as resulting from head injuries, brain operation and acute stage of cerebral infarction in adult only. For the treatment of patients with serious cerebral injuries of vascular traumatic nature with or without loss of consciousness & for treatment of degenerative damages & chronic cerebral vascular injuries in senile dementia. 4.2 Posology and Method of Administration The usually recommended dose of Citicoline is 500mg to 1000mg daily and can increase up to 2000mg. Elderly: No dosage adjustment is required in this patient population and the usually recommended adult dose can be administered. 4.3 Contraindications Hypersensitivity to citicoline or any other component of the formulation 4.4 Special Warnings and Special Precautions for Use: Citicoline may cause hypotension and in case necessary the hypotensive effect can be treated with corticosteroids or sympathomimetics. 4.5 Interaction with Other Medicinal Products and Other Forms of Interaction: Citicoline must not be used with medicines containing meclophenoxates (or centrophenoxine). Citicoline increases the effects of L-dopa. 4.6 Fertility, Pregnancy and Lactation There are no adequate and well controlled studies of citicoline during pregnancy and lactation. Citicoline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
    [Show full text]
  • More Treatments on Deck for Alcohol Use Disorder
    News & Analysis Medical News & Perspectives More Treatments on Deck for Alcohol Use Disorder Jeff Lyon hirteen years have passed since the Raye Z. Litten, PhD, acting director of the ment for AUD were actually prescribed an US Food and Drug Administration NIAAA’s Division of Medications Develop- AUD medication. T (FDA) last approved a new medica- ment and principal investigator of the trial, It is a complicated problem, says John tion to help the nation’s millions of people says the agency is “excited.” Rotrosen, MD, a psychiatrist and addiction withalcoholusedisorder(AUD)stopormod- Nevertheless, the science of alcohol ad- specialist at New York University School of erate their drinking. diction has seen its share of medicines that Medicine. “To a large extent primary care Only 3 such formulations exist, and 1, failed to live up to their early promise dur- physicians don’t screen for alcoholism,” he disulfiram, dates to the Prohibition era. ing full-scale testing. So Litten said the said. “When they do, they may note it, but Known commercially as Antabuse and agency isn’t putting all its eggs in one bas- don’t really do anything about it.” introduced in 1923, it makes people memo- ket. “You need as many weapons as pos- As far as the failure to prescribe exist- rably ill if they ingest alcohol, but it doesn’t sible to treat a complex disease like alcohol ing medications for AUD, Rotrosen blames stop the cravings. The other 2, naltrexone use disorder,” he said. a lack of knowledge. “A lot of doctors in and acamprosate, approved in 1994 and But therein lies a second difficulty.
    [Show full text]
  • Effect of Combined Therapy with Thrombolysis and Citicoline in a Rat
    Journal of the Neurological Sciences 247 (2006) 121–129 www.elsevier.com/locate/jns Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke ⁎ María Alonso de Leciñana a,e, , María Gutiérrez a,d, Jose María Roda a,c, Fernando Carceller a,c, Exuperio Díez-Tejedor a,b a Cerebrovascular Research Unit, La Paz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain b Department of Neurology, La Paz University Hospital, Madrid, Spain c Department of Neurosurgery, La Paz University Hospital, Madrid, Spain d Cerebrovascular Experimental Lab, La Paz University Hospital, Madrid, Spain e Department of Neurology, Ramón y Cajal University Hospital, Madrid, Spain Received 28 April 2005; received in revised form 3 January 2006; accepted 3 March 2006 Available online 22 June 2006 Abstract An approach combining reperfusion mediated by thrombolytics with pharmacological neuroprotection aimed at inhibiting the physiopathological disorders responsible for ischemia-reperfusion damage, could provide an optimal treatment of ischemic stroke. We investigate, in a rat embolic stroke model, the combination of rtPA with citicoline as compared to either alone as monotherapy, and whether the neuroprotector should be provided before or after thrombolysis to achieve a greater reduction of ischemic brain damage. One hundred and nine rats have been studied: four were sham-operated and the rest embolized in the right internal carotid artery with an autologous clot and divided among 5 groups: 1) control; 2) iv rtPA 5 mg/kg 30 min post-embolization 3) citicoline 250 mg/kg ip ×3 doses, 10 min, 24 h and 48 h post-embolization; 4) citicoline combined with rtPA following the same pattern; 5) rtPA combined with citicoline, with a first dose 10 min after thrombolysis.
    [Show full text]
  • Anticraving Therapy for Alcohol Use Disorder: a Clinical Review
    Received: 10 April 2018 | Revised: 11 June 2018 | Accepted: 11 June 2018 DOI: 10.1002/npr2.12028 INVITED REVIEW Anticraving therapy for alcohol use disorder: A clinical review Winston W. Shen1,2 1Department of Psychiatry, Wan Fang Medical Center, Taipei Medical University, Abstract Taipei, Taiwan Aim: In this review, the author focused on anticraving therapy for alcohol use disor- 2Department of Psychiatry, College of der (AUD) defined by DMS‐5. A comprehensive review was carried out on the avail- Medicine, Taipei Medical University, Taipei, Taiwan able published papers on anticraving drugs for treating AUD patients. Methods: The author described all drugs with anticraving benefits for treating Correspondence Winston W. Shen, Department of AUD patients approved by the Food and Drug Administration of the United States Psychiatry, Wan Fang Medical Center, No. (US FDA) and European Medicines Agency of the European Union. Then, the com- 111, Section 3, Hsing Long Road, Taipei 116, Taiwan. monly prescribed anticraving drugs and those under development were also Email: [email protected] described. Results: The US FDA‐approved anticraving drugs included acamprosate and naltrex- one, and those approved by European Medicines Agency were gamma‐hydroxybuty- rate and nalmefene. The author also highlighted topiramate, gabapentin, ondansetron, LY196044, ifenprodil, varenicline, ABT‐436, mifepristone, citicoline, and baclofen. The putative mechanisms of action of and the use in clinical practice of those anticraving drugs were also described. Conclusion: Although slowly developing, the field of anticraving drugs is getting into shape as a promising entity of a pharmaceutical class of drugs. Then, the author addressed on the underused issues of those recommended, and suggested anticraving drugs by the practice guideline of the American Psychiatric Association.
    [Show full text]
  • The Effect of Rosmarinic Acid on Apoptosis and Nnos Immunoreactivity Following Intrahippocampal Kainic Acid Injections in Rats
    Basic and Clinical January, February 2020, Volume 11, Number 1 Research Paper: The Effect of Rosmarinic Acid on Apoptosis and nNOS Immunoreactivity Following Intrahippocampal Kainic Acid Injections in Rats Safoura Khamse1* , Seyed Shahabeddin Sadr1,2 , Mehrdad Roghani3* , Mina Rashvand1 , Maryam Mohammadian4 , Narges Mare- fati1 , Elham Harati1 , Fatemeh Ebrahimi1 1. Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 2. Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. 3. Neurophysiology Research Center, Shahed University, Tehran, Iran. 4. Department of Physiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. Use your device to scan and read the article online Citation: Khamse, S., Sadr, Sh., Roghani, M., Rashvand, M., Mohammadian, M., & Marefati, N., et al. The Effect of Ros- marinic Acid on Apoptosis and nNOS Immunoreactivity Following Intrahippocampal Kainic Acid Injections in Rats Basic and Clinical Neuroscience, 11(1), 41-48. http://dx.doi.org/10.32598/bcn.9.10.340 http://dx.doi.org/10.32598/bcn.9.10.340 A B S T R A C T Introduction: Kainic Acid (KA) is an ionotropic glutamate receptor agonist. KA can induce neuronal overactivity and excitotoxicity. Rosmarinic Acid (RA) is a natural polyphenolic Article info: compound with antioxidant, anti-apoptotic, anti-neurodegenerative, and anti-inflammatory Received: 12 Apr 2018 properties. This study aimed to assess the effect of RA on apoptosis, nNOS-positive neurons First Revision: 10 May 2018 number, as well as Mitogen-Activated Protein Kinase (MAPK) and Cyclooxygenase-2 (COX- Accepted: 27 Oct 2018 2) immunoreactivity, following intrahippocampal Kainic acid injection in rats.
    [Show full text]
  • Kainic Acid-Induced Neurotoxicity: Targeting Glial Responses and Glia-Derived Cytokines
    388 Current Neuropharmacology, 2011, 9, 388-398 Kainic Acid-Induced Neurotoxicity: Targeting Glial Responses and Glia-Derived Cytokines Xing-Mei Zhang1 and Jie Zhu1,2, 1Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden; 2Department of Neurology, The First Hospital of Jilin University, Changchun, China Abstract: Glutamate excitotoxicity contributes to a variety of disorders in the central nervous system, which is triggered primarily by excessive Ca2+ influx arising from overstimulation of glutamate receptors, followed by disintegration of the endoplasmic reticulum (ER) membrane and ER stress, the generation and detoxification of reactive oxygen species as well as mitochondrial dysfunction, leading to neuronal apoptosis and necrosis. Kainic acid (KA), a potent agonist to the -amino- 3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate class of glutamate receptors, is 30-fold more potent in neuro- toxicity than glutamate. In rodents, KA injection resulted in recurrent seizures, behavioral changes and subsequent degeneration of selective populations of neurons in the brain, which has been widely used as a model to study the mechanisms of neurode- generative pathways induced by excitatory neurotransmitter. Microglial activation and astrocytes proliferation are the other characteristics of KA-induced neurodegeneration. The cytokines and other inflammatory molecules secreted by activated glia cells can modify the outcome of disease progression. Thus, anti-oxidant and anti-inflammatory treatment could attenuate or prevent KA-induced neurodegeneration. In this review, we summarized updated experimental data with regard to the KA-induced neurotoxicity in the brain and emphasized glial responses and glia-oriented cytokines, tumor necrosis factor-, interleukin (IL)-1, IL-12 and IL-18.
    [Show full text]
  • ( 12 ) United States Patent
    US010131766B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 131, 766 B2 Hazen et al. (45 ) Date of Patent: Nov . 20 , 2018 ( 54 ) UNSATURATED POLYESTER RESIN 6 ,619 ,886 B1 9 /2003 Harrington 6 ,692 , 802 B1 2 / 2004 Nava SYSTEM FOR CURED IN - PLACE PIPING 7 , 135 ,087 B2 11/ 2006 Blackmore et al. 7 ,799 ,228 B2 9 /2010 Bomak et al . (71 ) Applicant : Interplastic Corporation , Saint Paul, 8 , 047, 238 B2 11/ 2011 Wiessner et al . MN (US ) 8 ,053 ,031 B2 11/ 2011 Stanley et al. 8 ,092 ,689 B2 1 / 2012 Gosselin (72 ) Inventors : Benjamin R . Hazen , Roseville , MN 8 , 298 , 360 B2 10 / 2012 Da Silveira et al. 8 ,418 , 728 B1 4 / 2013 Kiest , Jr . (US ) ; David J . Herzog , Maple Grove , 8 ,586 ,653 B2 11 / 2013 Klopsch et al. MN (US ) ; Louis R . Ross, Cincinnati , 8 ,636 , 869 B2 1 / 2014 Wiessner et al . OH (US ) ; Joel R . Weber , Moundsview , 8 ,741 , 988 B2 6 /2014 Klopsch et al. MN (US ) 8 , 877 , 837 B2 11/ 2014 Yu et al. 9 ,068 , 045 B2 6 /2015 Nava et al. 9 ,074 , 040 B2 7 / 2015 Turshani et al. ( 73 ) Assignee : Interplastic Corporation , St. Paul , MN 9 , 150 , 709 B2 10 / 2015 Klopsch et al . (US ) 9 , 207 , 155 B1 12 / 2015 Allouche et al. 9 ,273 ,815 B2 3 / 2016 Gillanders et al. ( * ) Notice : Subject to any disclaimer, the term of this 9 , 371, 950 B2 6 / 2016 Hairston et al. patent is extended or adjusted under 35 9 , 550 , 933 B2 1 /2017 Chatterji et al .
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Electrophysiological Mechanisms of Kainic Acid- Induced Epileptiform Activity in the Rat Hippocampal Slice’
    0270-6474/84/0405-1312$02,00/O The Journal of Neuroscience Copyright 0 Society for Neuroscience Vol. 4, No. 5, pp. 1312-1323 Printed in U.S.A. May 1984 ELECTROPHYSIOLOGICAL MECHANISMS OF KAINIC ACID- INDUCED EPILEPTIFORM ACTIVITY IN THE RAT HIPPOCAMPAL SLICE’ ROBERT S. FISHER’ AND BRADLEY E. ALGER Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201 Received August 29, 1983; Revised December 28, 1983; Accepted January 4, 1984 Abstract Depression of GABA-mediated IPSPs has been proposed to be a crucial factor in the onset of epileptiform activity in most models of epilepsy. To test this idea, we studied epileptiform activity induced by bath application of the excitatory neurotoxin kainic acid (KA) in the rat hippocampal slice. Repetitive field potential firing, spontaneous or evoked, occurred during exposure to KA. Intracellular records from 52 CA1 pyramidal cells during changes from control saline to saline containing i PM KA indicated that KA depolarized cells an average of about 5 mV and caused a 15% decrease in input resistance. Action potentials and current-induced burst afterhyperpolariza- tions did not change significantly. In several cells the tonic effects of KA were preceded by a transient phase of sporadic, spontaneous depolarizations of 2 to 10 mV and 50 to 200 msec duration. These phasic depolarizations were blocked by hyperpolarization. The major effect of 1 PM KA was a depression of synaptic potentials. Initially, KA depressed fast GABA-mediated IPSPs and slow, non-GABA-mediated late hyperpolarizing potentials to 23% and 40% of control values, respectively. IPSP depression correlated closely with onset of burst potential firing in response to synaptic stimulation.
    [Show full text]
  • Impact of Citicoline Over Cognitive Impairments After General Anesthesia
    International Journal of Science and Research (IJSR) ISSN: 2319-7064 ResearchGate Impact Factor (2018): 0.28 | SJIF (2018): 7.426 Impact of Citicoline over Cognitive Impairments after General Anesthesia Kameliya Tsvetanova Department “Anesthesiology and Resuscitation“, Medical University – Pleven, Bulgaria Abstract: Postoperative cognitive delirium - POCD is chronic damage with deterioration of the memory, the attention and the speed of the processing of the information after anesthesia and operation. It is admitted that anesthetics and other perioperative factors are able to cause cognitive impairments through induction of apoptosis, neuro-inflammation, mitochondrial dysfunction and so on. More and more medicaments are used in modern medicine, as, for instance, Citicoline, which are in a position significantly to reduce this unpleasant complication of the anesthesia. Keywords: Postoperative cognitive delirium, anesthesia, Citicoline. 1. Introduction Therefore, Citocoline is the main intracellular precursor of phospholipid phosphatidyl choline. (13), (14), (15), (16), It is known that anesthetics and other perioperative factors (17), (18), (19), (20), (21), (22), (23), (24), (25), (26) are able to cause cognitive impairments through induction of apoptosis, neuro-inflammation, mitochondrial dysfunction It exerts impact over the cholinergic system and acts as a and so on. choline donor for the enhanced synthesis of acetylcholine. Chronic damage with deterioration of the memory, the attention and the speed of the processing of the information
    [Show full text]
  • NMDA Agonists Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of NMDA Agonists Using ALZET Osmotic Pumps Aspartic Acid P7453: M. Domercq, et al. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia 2005;52(1):36-46 ALZET Comments: Oligonucleotide, antisense; oligonucleotide sense; kainate, dihydro-; aspartic acid, DL-threo-B-benzyloxy-; Saline, sterile; CSF/CNS (optic nerve); Rabbit; 1003D; 3 days; Controls received mp w/ vehicle, or contralateral nerves; antisense (glutamate transporters GLAST + GLT-1); animal info (adult, male, white New Zealand). P6888: J. Darman, et al. Viral-induced spinal motor neuron death is non-cell-autonomous and involves glutamate excitotoxicity. Journal of Neuroscience 2004;24(34):7566-7575 ALZET Comments: Aspartic acid, dl-threo-B-hydroxy; spermine, 1-naphthyl acetyl; CSF/CNS (intrathecal, subarachnoid space); Rat; 1007D; 7 days; Controls received mp w/ saline; enzyme inhibitors (GLT-1, GluR2). P3908: A. Hirata, et al. AMPA receptor-mediated slow neuronal death in the rat spinal cord induced by long-term blockade of glutamate transporters with THA. Brain Research 1997;771(37-44 ALZET Comments: Aspartic acid, dl-threo-B-hydroxy; Glutamate, l-; CSF, artificial;; CSF/CNS (subarachnoid space, intrathecal); Rat; 2ML1; no duration posted; dose-response; cannula position verified. P0289: R. M. Mangano, et al. Chronic infusion of endogenous excitatory amino acids into rat striatum and hippocampus. Brain Res. Bull 1983;10(47-51 ALZET Comments: Aminobutyric acid, Y-; Aspartic acid, dl-threo-B-hydroxy; Aspartic acid, l-; Cysteine sulfinic acid; Glutamic acid, l-; Radio-isotopes; 3H tracer; Acetate; Saline; CSF/CNS (corpus striatum); CSF/CNS (hippocampus); Rat; 2002; 2 weeks; comparison of injec.
    [Show full text]